Clinical Trial Update: Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lenalidomide with rituximab as front-line therapy for diffuse large B-cell lymphoma in patients over 80 years old.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Diffuse Large B Cell Lymphoma, Age Over 80 Years | Phase 2 | Status: UNKNOWN